IP strenghtening for MIDRIX, a unique manufacturing process for dendritic cell immunotherapy in solid cancers

01 April 2019 → 31 August 2020
Regional and community funding: Industrial Research Fund
Research disciplines
  • Medical and health sciences
    • Immunology not elsewhere classified
Dendritic cell therapy non-small cell lung cancer
Project description

The preclinical development of a unique dendritic cell vaccine against lung cancer has been completed. This cellular immunotherapy is aimed at a growing unmet need in this patient population. A spin-off is being developed to raise the required capital in order to continue a successful phase Ia study to a phase Ib and phase II study. A number of experiments are planned to strengthen the patent position.